The Swiss drug giant Novartis AG, moving to establish itself as a top player in the hot field of cancer treatment known as immunotherapy, on Monday said it had snapped up two-year-old CoStim Pharmaceuticals Inc., a venture-backed Cambridge biotech using research from Boston academic labs.
Retired biotechnology executive Henri A. Termeer, who built Genzyme Corp. into the largest US company specializing in drugs to treat rare genetic disorders, is donating $10 million to Massachusetts General Hospital to establish it as a world leader in personalized medicine.
With his appointment Monday to lead the National Economic Council, the brainy but abrasive Lawrence H. Summers ’75 is set to become a key ideas man for President-elect Barack Obama as he labors to keep the economic crisis from spiraling out of control.
Last week, Harvard Business School mounted its own emergency rescue mission on Wall Street.
The annual mating ritual between elite business schools and the talent-hungry technology industry this year lured a record 115 master of business administration candidates from MIT’s Sloan School of Management in Cambridge to the hillside campus of VMware Inc., one of Silicon Valley’s hottest companies.
Will the car of the future be foldable?
MIT officials have tapped an outsider, David C. Schmittlein, deputy dean of the elite Wharton School at the University of Pennsylvania, to lead MIT’s Sloan School of Management.